The World Health Organization (WHO) has added the first molecular diagnostic test for Bundibugyo virus (BDBV)—the cause of Ebola disease—to its Emergency Use Listing (EUL). The test is designed to detect BDBV genetic material in blood samples, enabling faster and more accurate confirmation of infection during outbreaks. WHO says the EUL process evaluates the quality, safety, and performance of essential health products against minimum international standards, with attention to the needs of low- and middle-income countries. WHO also notes that EUL supports procurement decisions by UN agencies and governments for public health emergencies.

WHO reports that it declared a public health emergency of international concern for Ebola disease caused by BDBV in the Democratic Republic of the Congo, with cases in Uganda, on 17 May 2026. It says laboratory testing capacity has expanded from a limited number of sites to a wider network across affected provinces. WHO states that, as of the latest reported figures, 1,406 laboratory-confirmed cases and 438 deaths have been reported in the DRC. Additional applications for BDBV diagnostic tests are under review, and WHO and partners are working on a validation platform to assess product performance in outbreak conditions.